Scarica l'app Stockscreener
202.72
0.71%
1.42
Dopo l'orario di chiusura:
202.75
0.03
+0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$201.30
Aprire:
$202.02
Volume 24 ore:
4.49M
Relative Volume:
0.80
Capitalizzazione di mercato:
$358.61B
Reddito:
$56.33B
Utile/perdita netta:
$4.28B
Rapporto P/E:
84.47
EPS:
2.4
Flusso di cassa netto:
$17.83B
1 W Prestazione:
-4.36%
1M Prestazione:
-1.12%
6M Prestazione:
+4.07%
1 anno Prestazione:
+12.40%
Intervallo 1D:
$201.30
$203.68
Intervallo di 1 settimana:
$196.49
$212.88
Portata 52W:
$153.58
$218.66
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Confronta ABBV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
202.72 | 358.61B | 56.33B | 4.28B | 17.83B | 2.40 |
|
LLY
Lilly Eli Co
|
821.67 | 738.00B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
163.13 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
70.16 | 311.44B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
87.60 | 221.28B | 64.17B | 17.12B | 18.10B | 6.73 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie shares rose after seven consecutive sessions of losses (NYSE:ABBV) - Seeking Alpha
Corticosteroids Market May See a Big Move | Major Giants- AbbVie, Astellas Pharma, AstraZeneca - openPR
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
AbbVie (NYSE:ABBV) Showcases Oncology Innovations Amidst 6% Share Price Dip - Yahoo Finance
Non-Small Cell Lung Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca - Barchart
AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025 - PR Newswire
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market - MSN
AbbVie accuses oncology partner of stealing trade secrets - Crain's Chicago Business
AbbVie Inc (ABBV) Shares Gap Down to $202.37 on Mar 25 - GuruFocus.com
Smart Money Is Betting Big In ABBV OptionsAbbVie (NYSE:ABBV) - Benzinga
AbbVie sues Genmab, claiming trade secrets theft - pharmaphorum
AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Abbvie CEO Robert A. Michael's 2024 Total Compensation Was $18.5 MillionFiling -March 24, 2025 at 04:44 pm EDT - Marketscreener.com
AbbVie lawsuit alleges that partner Genmab “misappropriated” trade secrets - PharmaLive
Genmab stock falls amid AbbVie lawsuit By Investing.com - Investing.com South Africa
Genmab to Defend Against AbbVie’s Trade Secret Misappropriation Claims - TipRanks
Genmab stock falls amid AbbVie lawsuit - Investing.com
AbbVie Lawsuit Alleges That Partner Genmab "Misappropriated” Trade Secrets - BioSpace
Genmab faces trade secret claims by AbbVie - Investing.com India
Genmab Denies Trade Secret Misappropriation Claims by AbbVie -March 24, 2025 at 08:21 am EDT - Marketscreener.com
Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025 - PR Newswire
Genmab dismisses Abbvie lawsuitaccused of exploiting trade secrets -March 24, 2025 at 03:30 am EDT - Marketscreener.com
Global Autoimmune Disease Therapeutics Market to reach USD 226,194.0 Million by 2035 Amid Rising Prevalence and Advancements in Biologic Therapies | Future Market Insights, Inc. - GlobeNewswire Inc.
Is AbbVie Inc. (ABBV) The Best Healthcare Dividend Stock to Invest in? - Insider Monkey
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. - GlobeNewswire
Genmab To Vigorously Defend Alleged Claims Of Trade Secret Misappropriation By Abbvie Inc. - Marketscreener.com
Is AbbVie Gaining or Losing Market Support?AbbVie (NYSE:ABBV) - Benzinga
Non-Small Cell Lung Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo - Barchart
Open Angle Glaucoma Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Visiox Pharma, TearClear, VivaVision Biotech, Inc., Abbvie, Ocuphire Pharma, Qlaris Bio, Inc - The Globe and Mail
Botox Market Demand, Growth, Demand and Future Scope 2025-2032 | - openPR
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease - MSN
AbbVie Options Trading: A Deep Dive into Market Sentiment - Benzinga
Advancing Oncology: Innovations in Treatment and Detection - Value the Markets
Parkinson’s Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail Therapeutics, Amnea - Barchart
Alzheimers Drugs Market Is Booming Worldwide | AbbVie, Inc., Teva Pharmaceuticals Ltd., Eisai Co., Ltd - openPR
Abbvie Inc. (ABBV) Elliott Wave technical analysis [Video] - FXStreet
Immunology Drugs Market Key Players AnalysisEli Lilly, AbbVie Inc, F.Hoffmann-La roche Ltd, Amgen Inc, Pfizer. - openPR
Transitional Cell Carcinoma Treatment Market Size in 7MM - openPR
AbbVie (ABBV) Stock Moves -0.29%: What You Should Know - Yahoo Finance
AbbVie CFO Scott Reents sells $3.75 million in stock By Investing.com - Investing.com Australia
AbbVie CFO Scott Reents sells $3.75 million in stock - Investing.com
Endometriosis Pain Pipeline 2025: FDA Approvals and Clinical - openPR
Widely used drugs on US imports list from Europe - Reuters.com
AbbVie upgraded to Buy at Erste Group on Friday - Yahoo Finance
AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients - Benzinga India
AbbVie’s Elahere demonstrates extended survival in Phase 3 MIRASOL trial - World Pharmaceutical Frontiers
Erste Group lifts AbbVie stock rating to Buy on growth forecast - Investing.com UK
AbbVie reports final analysis from Phase III trial of Elahere for ovarian cancer - Yahoo Finance
The Zacks Analyst Blog Highlights AbbVie, Lockheed Martin, Dell and Hamilton Beach Brands - Nasdaq
AbbVie builds the case for ovarian cancer drug Elahere - pharmaphorum
AbbVie (NYSE:ABBV) Reports ELAHERE Success in Phase 3 Trials for Platinum-Resistant Ovarian Cancer - Yahoo Finance
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
2.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):